ALZ-801 promotes amyloid clearance from brain 

Amyloid-oligomers-drive-neurotoxicity-and-tau-pathology_Alzheon

Milà-Alomà (2022) Nat Med; Hansson (2021) Nat Med, Karikari (2020) Lancet Neurol

Amyloid oligomers drive neurotoxicity & tau pathology

Injured neurons release misfolded tau protein that aggregates into tangles

Plasma p-tau181 reduction predicts clinical efficacy

Gantenerumab – AAIC 2022; Roche GRADUATE Phase 3 Studies Press Release, November 2022
Aducanumab – AAIC 2021 & CTAD 2021
Lecanemab – CTAD 2021; Swanson (2020) Alz Res Therapy; Eisai CLARITY AD Phase 3 Study Press Release, September 2022
ALZ-801 – CTAD 2022

Amyloid clearance from brain to plasma via astrocyte end-feet on capillaries & by glial uptake

Tarasof-Conway (2015) Nat Rev Neurol & Bagheri (2013) PLOS One

ALZ-801 blocks amyloid aggregation in brain, promotes efflux of monomers to plasma & activation of astrocytes

ALZ-801 Blocks Amyloid Aggregation

Tarasof-Conway (2015) Nat Rev Neurol & Bagheri (2013) PLOS One

Assay to measure neurotoxic amyloid oligomers in brain

  • Alzheon collaborates with Czech Institute of Organic Chemistry & Biochemistry to develop commercial assay to measure neurotoxic amyloid oligomers in brain
  • Diagnostic & theragnostic assay enables early intervention with ALZ-801
  • Measurement of brain oligomer burden enables treatment & prevention:
    1. Monitoring of progress & assessment of treatment impact in patients
    2. Intervention years before emergence of clinical symptoms in cognitively normal individuals with increased risk for Alzheimer’s

Mass spectrometry detects soluble amyloid oligomers

Kocis (2017) CNS Drugs